Cancer Tracer Tilmanocept Iran Becomes World’s Second Producer
An Iranian knowledge-based company has developed an innovative method to synthesize Technetium (99mTc) Tilmanocept. This radiopharmaceutical imaging agent helps identify lymph nodes draining from tumors, improving surgical precision and reducing unnecessary procedures. Notably, Iran has become the world’s second producer of this Cancer Tracer, ending the United States’ monopoly since 2013. Consequently, this advancement provides Iranian cancer patients with a more affordable and accurate diagnostic option, significantly enhancing the nation’s role in global cancer care.
The Importance of Accurate Lymph Node Detection
The lymphatic system is one of the main conduits of cancer metastasis. In patients with breast, lung, and genital tract cancers, accurate detection of lymph node involvement is critical for surgeons. Failure to identify involved lymph nodes in time can lead to the removal of large parts of the lymphatic system, causing numerous side effects for patients and affecting their immune system and blood circulation.
Revolutionizing Cancer Diagnosis and Treatment
This radiodiagnostic agent enables doctors to identify lymph nodes for surgical removal while preserving healthy ones and avoiding complications. With this innovation, approximately 90% of cancer patients nationwide will access Cancer Tracer, a more cost-effective and precise diagnostic and treatment method using Tilmanocept.
Cancer: A Global Health Challenge
Cancer is one of the leading causes of premature mortality in Iran, accounting for more than 55 thousand deaths annually. The latest national cancer census shows that the number of new cancer cases in Iran is expected to increase to 160,000 by the Iranian calendar year 1404 (March 2025-March 2026), indicating an increase of 43 percent.
Common Cancers in Iran
In Iran, the most common cancers include breast, prostate, colon, stomach, lung, bladder, thyroid, uterus, brain, and spine cancers. Breast cancer remains the leading type among women, causing approximately 30% of patient deaths annually despite advancements like Cancer Tracer and Tilmanocept.
Recent Achievements in Cancer Research
Iran has made notable advancements in cancer research and treatment. On January 20, 2024, the Iran University of Medical Sciences (IUMS) introduced an AI-powered system that detects breast cancer with 94% accuracy. Additionally, an Iranian knowledge-based company has prepared to supply human papillomavirus (HPV) vaccines to regional and North African countries. This vaccine, priced 75% lower than global alternatives, complements innovations like Cancer Tracer and Tilmanocept in improving global cancer care.
Ibrutinib: A Breakthrough in Blood Cancer Treatment
In September 2023, an Iranian knowledge-based company successfully produced ibrutinib, a drug treating blood cancers, after five years of research. This achievement makes Iran the third country, alongside India and China, capable of producing ibrutinib and its raw materials. With this milestone, Iran has advanced cancer care by offering a cost-effective alternative to imported options. Additionally, as the world’s second producer of Tilmanocept, Iran continues to innovate with tools like Cancer Tracer to improve global cancer diagnosis and treatment.
Source: Tehran Times